

# Company Overview

argenta 

## Location/Site/Business

- Auckland, New Zealand
- Older human pharmaceuticals site
- Completely refurbished by Nufarm in mid-90s
- Significant Merck Manufacturing consultation advice during refurbishment and fit-out (~NZ\$42M)
- New flammables building completed 2006
- Business/Site purchased by ChemLabs in Aug 2006
- Argenta formed from ChemLabs and unit purchased from Nufarm
- Successful US-FDA PAI in mid-2007

Auckland



# Argenta Ownership

- Doug Cleverly (CEO)
- Gary Harrison (Operations)
- Glenn Boyes (Finance)
- ANZ Capital

## Facility Overview


- World's first Contract Development and Manufacturing Organization (CDMO), Dedicated to Animal Health
- Accreditations – NZ / AU / EU / US FDA
- Exports to > 40 countries
- Administration Area – 11,400 sq ft
- Factory/Lab Areas – 77,100 sq ft
- Land Area – 2.59 Ha / 6.4 acres

## Staff Numbers and Distribution

Production	52
Quality Control	18
Quality Assurance	9
Administration	8
Research & Development	21
<b>TOTAL</b>	<b>108</b>

# Staff

## Organizational Structure



## Qualification/Experience of Senior Staff

- Doug Cleverly - CEO
  - PhD Biophysical Chemistry
  - Nufarm R&D Manager, Director/Head of Formulation Development, Merial USA
- Gary Harrison – Head of Operations
  - BSc/BEng (Chem)
  - 12 years with Nufarm AH manufacturing
- Karin Austurian – Head of QAU
  - Ex Amgen USA
- Jane Eagleson – Business Development
  - DVM
  - Ex Director Merck/Merial USA & Senior Director Pfizer USA/India

# Business Model

- Contract service provider
  - Formulation/Analytical R&D
  - CMC development
  - Toll Manufacturing
  - R&D feeds manufacturing facility
- Respect for IP
  - No copies of products that Argenta is developing or manufactures
  - No generics containing patent protected APIs/technology
- Documentation to format required by target regulatory agency(s)

# Business Plan

- Operate as an Independent Turnkey Service Provider
  - Dedicated to Animal Health
  - Ownership is private with minority bank equity
  - Argenta does not market its own products
- Growth Strategies
  - Companion animal R&D and manufacturing
  - Focus on supply to the EU and USA
  - Development of platform technologies
  - Extend services to include (in planning)
    - Clinical trial management provider
    - Logistics and distribution support
    - Large volume ectoparasiticide production, compliant

# Core Competencies – Research & Development

## Research and Development Capabilities

- Preformulation
  - NCE characterization
  - Drug / excipient interaction
- Formulation Development
  - Express Formulation Screening (EFS) technique
  - Across all dosage forms
- Analytical Development
  - 14 HPLC's
  - LCMS capability
- CMC Development
  - All chemistry and manufacturing related sections
- Regulatory Support
  - Preparation of regulatory dossiers
- Clinical Support – own research herd, expanding services

# Core Competencies - Manufacturing

## Production Capabilities

- Solid Dose
  - Powders, granules tablets
  - Palatable chewable treats
- Controlled Release Technologies
  - Intra-ruminal capsules, bolus
- Sterile Liquids
- Non-Flammable Liquids
  - Pour ons, orals, gels, suspensions
- Flammable Liquids
  - Pour-ons and other topicals

# Site Specifics

argentā



## Research & Development



## Pilot Plant (Scale Up)



## Aqueous Liquids



# Flammables Facility



## Flammables Facility



## Solid Dosage



## Sterile Liquids



# Quality Control



